Moderna, Inc. (NASDAQ:MRNA) Shares Bought by Swedbank AB

Swedbank AB grew its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 149.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 85,099 shares of the company's stock after buying an additional 51,000 shares during the quarter. Swedbank AB's holdings in Moderna were worth $5,687,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Polianta Ltd purchased a new stake in Moderna during the 3rd quarter valued at $835,000. Douglas Lane & Associates LLC raised its stake in shares of Moderna by 17.5% in the third quarter. Douglas Lane & Associates LLC now owns 475,089 shares of the company's stock valued at $31,750,000 after acquiring an additional 70,889 shares during the period. Willner & Heller LLC purchased a new stake in shares of Moderna in the third quarter valued at $488,000. Exchange Traded Concepts LLC lifted its holdings in shares of Moderna by 164.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 17,558 shares of the company's stock worth $1,173,000 after acquiring an additional 10,907 shares during the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt boosted its stake in shares of Moderna by 278.2% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 2,772 shares of the company's stock worth $185,000 after purchasing an additional 2,039 shares during the period. Institutional investors own 75.33% of the company's stock.

Insider Transactions at Moderna

In other Moderna news, CFO James M. Mock sold 1,321 shares of the firm's stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Moderna news, CFO James M. Mock sold 1,321 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the business's stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $119.96, for a total value of $1,799,400.00. Following the sale, the director now owns 2,224,015 shares in the company, valued at $266,792,839.40. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 33,184 shares of company stock valued at $3,804,931 in the last 90 days. Insiders own 15.70% of the company's stock.

Moderna Stock Down 1.3 %

Moderna stock traded down $0.72 during mid-day trading on Friday, reaching $54.10. 6,754,694 shares of the company were exchanged, compared to its average volume of 4,347,810. Moderna, Inc. has a 12-month low of $53.55 and a 12-month high of $170.47. The business has a fifty day moving average of $70.75 and a 200 day moving average of $104.57. The firm has a market cap of $20.73 billion, a P/E ratio of -3.45 and a beta of 1.66. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating analysts' consensus estimates of ($3.47) by $0.14. The company had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm's revenue for the quarter was down 29.9% compared to the same quarter last year. During the same quarter last year, the company earned ($3.62) earnings per share. Research analysts anticipate that Moderna, Inc. will post -9.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MRNA has been the topic of a number of recent analyst reports. Barclays reduced their price objective on shares of Moderna from $155.00 to $125.00 and set an "overweight" rating on the stock in a research report on Monday, September 16th. William Blair reissued a "market perform" rating on shares of Moderna in a research note on Thursday, June 27th. Hsbc Global Res raised Moderna from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 28th. JPMorgan Chase & Co. downgraded Moderna from a "neutral" rating to an "underweight" rating and decreased their target price for the stock from $88.00 to $70.00 in a research report on Friday, September 13th. Finally, Royal Bank of Canada restated a "sector perform" rating and issued a $75.00 price target on shares of Moderna in a report on Thursday, September 19th. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat, Moderna currently has an average rating of "Hold" and a consensus target price of $97.18.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.